Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy (IDEAL-VMAT)
This study has been terminated.
(Lack of accrual)
Sponsor:
Radboud University
Information provided by (Responsible Party):
Jan Bussink, Radboud University
ClinicalTrials.gov Identifier:
NCT01577212
First received: March 16, 2012
Last updated: November 6, 2015
Last verified: November 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this present study is to test the feasibility and toxicity of individualized hypofractionated radiotherapy, and to report outcome data. In case this phase II trial has favorable results, a phase II/III trial on maximally tolerable, individualized, hypofractionated radiotherapy within a shorter overall-treatment time is aimed for.
| Condition | Intervention | Phase |
|---|---|---|
|
Stage III Non-small Cell Lung Cancer Individualized Radiation Dose Escalation |
Radiation: Individualized dose escalation |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Individualized Dose Escalation for Non-small Cell Lung Cancer (NSCLC) Using Volumetric Modulated Arc Therapy (VMAT) |
Resource links provided by NLM:
Further study details as provided by Radboud University:
Primary Outcome Measures:
- Pulmonary toxicity grade 2-4 [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- Esophageal toxicity grade 2-4 [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Increase in tumor control probability (TCP) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Local-regional failure [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Quality of life [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Enrollment: | 6 |
| Study Start Date: | March 2012 |
| Study Completion Date: | September 2014 |
| Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Individualized dose escalation
Individualized dose escalation on the basis of the dose to the organs at risk.
|
Radiation: Individualized dose escalation
Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed stage IIIA/B NSCLC (excluding pleural effusion and mixed pathology)
- Irresectable disease (as assessed by multidisciplinary team) or patient refusing surgery
- Disease which can be encompassed within a radical radiotherapy treatment plan in keeping with standard practice at the participating center
- Proposed treatment consists of radiotherapy alone or concurrent chemoradiation
- WHO performance status 0 or 1
- Adequate respiratory function: FEV1 ≥ 1.5 L and DLCO > 40%, predicted on baseline pulmonary function tests
- Age ≥ 18 years, no upper age limit
- Estimated life expectancy of more than 6 months
- Patient is available for follow-up
- Written informed consent obtained
Exclusion Criteria:
- Clinically diagnosed NSCLC
- Previous or current malignant disease likely to interfere with the protocol treatment or comparisons
- Prior thoracic radiotherapy
- Proposed treatment consist of sequential chemoradiation
- Prior lobectomy / pneumonectomy
- Prior chemotherapy using gemcitabine or bleomycine
- Superior sulcus tumors if the brachial plexus is within the high-dose volume
- Medically unstable (e.g., ischaemic heart disease, esophageal disorders)
- Pregnancy
- Connective tissue disorders
- Abnormal kidney function interfering with administration of iv contrast agent (GFR<60)
- Uncontrolled diabetes mellitus hampering 18FDG-PET
- Inability to comply with protocol or trial procedures
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01577212
Please refer to this study by its ClinicalTrials.gov identifier: NCT01577212
Locations
| Netherlands | |
| Radboud University Nijmegen Medical Centre | |
| Nijmegen, Netherlands, 6500 HB | |
Sponsors and Collaborators
Radboud University
Investigators
| Principal Investigator: | Jan Bussink, MD PhD | Radboud University |
| Principal Investigator: | Esther GC Troost, MD PhD | Radboud University |
| Principal Investigator: | Robin Wijsman, MD | Radboud University |
| Principal Investigator: | Aswin L Hoffmann, MSc | Maastro Clinic, The Netherlands |
| Principal Investigator: | Lioe-Fee de Geus-Oei, MD PhD | Radboud University |
More Information
| Responsible Party: | Jan Bussink, Associate Professor, Radboud University |
| ClinicalTrials.gov Identifier: | NCT01577212 History of Changes |
| Other Study ID Numbers: | CMO 2011/345 NL nr 35536.091.11 |
| Study First Received: | March 16, 2012 |
| Last Updated: | November 6, 2015 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Radboud University:
|
stage III NSCLC (chemo)radiotherapy individualized dose-escalation |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
ClinicalTrials.gov processed this record on September 23, 2016